VIDEO: Shapiro discusses need for standardization of biologic products, procedures
Click Here to Manage Email Alerts
Key takeaways:
- Biologic therapy requires standardization for the treatment of musculoskeletal conditions.
- Surgeons must understand the mechanism of action, dosing and potency in order to advance products and devices.
WASHINGTON — In this video from the American Academy of Orthopaedic Surgeons Next Generation of Biologics Symposium, Shane A. Shapiro, MD, spoke about the need to standardize biologic therapies for musculoskeletal conditions.
The symposium was presented in collaboration with the Biologic Association.
“What we really need to see more of — and what we talked a lot about today — was how we standardize these treatments, because we are not going to see growth in this field without a better understanding of what is the therapeutic mechanism of action for a number of these treatments and perhaps a lot of discussion about dosing and potency,” Shapiro said.
“As we look to bring both biologic products and devices through the pipeline for more approvals in the field of orthopedics, those are things we are looking at,” he concluded.
Collapse
Read more about
Click Here to Manage Email Alerts